Citations

Clear

6273 citation(s) found for "To, Andrew".

Outcomes of Venovenous Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia: A Multicenter Retrospective Case Series
Pulsipher, Aaron M. , Henry, Kyle, Cartin‐Ceba, Rodrigo , Lee, Augustine S. , Patel, B. M. , Miller, Brittany, Thompson, Emily , Sen, Ayan , Ham, Kealy R., Lee, Augustine, Thompson, Emily R , Pulsipher, Aaron M , Vikram, Holenarasipur R. , Gotway, Michael B. , Limper, Andrew H. , Miller, Brittany

Mayo Clinic

Critical Care Explorations | August 4, 2025 | Volume: 7 | Issue: 8 | Pages: e1296

10.1097/cce.0000000000001296 | PMID 40758332 Get It

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection increasingly recognized among non-HIV immunocompromised patients. In severe cases progressing to acute respiratory distress syndrome, venovenous extracorporeal membrane oxygenation (VV-ECMO) may serve as a rescue therapy. We conducted a retrospective multicenter review of 10 adult patients with proven or probable PCP who received VV-ECMO between 2017 and 2024. Seven of 10 patients survived to discharge, including all three HIV-positive patients and 4 of 7 non-HIV immunocompromised patients. The mean Respiratory ECMO Survival Prediction Score was –1.5, corresponding to a predicted survival of 33–57%. Multiorgan dysfunction was common, including renal failure requiring dialysis in 6 of 10 patients, need for neuromuscular blockade in 8 of 10, and pulmonary vasodilator use in 8 of 10. Despite high acuity and prolonged ECMO support, outcomes were favorable. These findings suggest that VV-ECMO may be a viable salvage therapy for select patients with severe PCP, including those without HIV.
Design considerations for C9orf72 disease prevention trials
Benatar, Michael , Staffaroni, Adam M. , Wuu, Joanne , McDermott, Michael P. , Quintana, Melanie , Swidler, Jean , Andersen, Gail, Huey, Edward D. , Turner, Martin R. , Macklin, Eric A. , Gendron, Tania, Onyike, Chiadi U. , Rosen, Howard J. , Heuer, Hilary W. , Grignon, Anne‐Laure , Dave, Kuldip D. , Balas, Calaneet, Satlin, Andrew , Dunn, Billy , Dacks, Penny A. , Boxer, Adam L. , Berry, James D , McMillan, Corey T , Gendron, Tania F , Onyike, Chiadi , Rosen, Howard J , Heuer, Hilary W , Grignon, Anne-Laure , Satlin, Andrew , Dacks, Penny , Boxer, Adam , Turner, Martin R , Wuu, Joanne , Andersen, Gail, Berry, James D. , McMillan, Corey T. , Gendron, Tania F. , Gleixner, Amanda M.

Mayo Clinic

Brain | August 3, 2025 | Volume: 148 | Issue: 11 | Pages: 3844-3855

10.1093/brain/awaf290 | PMID 40794569 Get It

Abstract The idea that it might be possible to prevent some forms of amyotrophic lateral sclerosis and frontotemporal dementia has finally come of age. The hexanucleotide repeat expansion in the C9orf72 gene accounts for ∼10% of all amyotrophic lateral sclerosis and 10%–15% of all frontotemporal dementia diagnoses, with the two clinical syndromes co-manifesting in a significant number of patients. As a result, clinically unaffected carriers of pathogenic C9orf72 repeat expansions are currently the largest identifiable population at significantly elevated risk for both amyotrophic lateral sclerosis and frontotemporal dementia, and in whom it might be possible to prevent the emergence of clinically manifest disease. Strategies for the design of disease prevention trials among clinically unaffected C9orf72 carriers have begun to emerge separately in the amyotrophic lateral sclerosis and frontotemporal dementia fields. However, recognition of the need to define neurodegenerative diseases based on biology underscores the need to consider all potential clinical manifestations of a C9orf72 repeat expansion together, rather than the traditional siloed approach of focusing on only amyotrophic lateral sclerosis or only frontotemporal dementia. Indeed, emerging clinical and biological markers that might be used to quantify pre-symptomatic disease progression and to predict the short-term risk of phenoconversion to clinically manifest disease are shared across the phenotypic spectrum. Given the anticipated progress in the development of therapeutic strategies to target the C9orf72 repeat expansion, and the enthusiasm for prevention trials among the unaffected C9orf72 repeat expansion carrier population, now is the time to begin work on the design of disease prevention trials. To this end, The Association for Frontotemporal Degeneration and The ALS Association supported a multi-stakeholder workshop (in Washington D.C., June 2024) to unify efforts to design a prevention trial for the population at elevated genetic risk for the phenotypic spectrum of C9orf72 disease. Here we describe recommendations emanating from this workshop for the selection of outcome measures, delineation of eligibility criteria, optimal use of biomarkers and digital health technologies, potential analytic frameworks and relevant regulatory considerations related to C9orf72 disease prevention trials. We also emphasize the importance of the amyotrophic lateral sclerosis and frontotemporal dementia communities working together in partnership with the C9orf72 repeat expansion carrier community, the regulatory authorities and the broader drug development community.
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Dhakal, Binod , Akhtar, Othman Salim , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed, Martinez, Mariola Alejandra Vazquez, Wagner, Charlotte B , Davis, James A. , Afrough, Aimaz , Bhutani, Manisha , Freeman, Ciara L. , Mikkilineni, Lekha , Raza, Shahzad , Anderson, Larry D. , Kapoor, Prashant , Hosoya, Hitomi , Gaballa, Mahmoud , Midha, Shonali , Alsina, Melissa , Sborov, Douglas W. , Patel, Krina K. , Lin, Yi , Ferreri, Christopher J. , Kumar, Anupama, Cowan, Andrew J., Sidana, Surbhi , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed , Vazquez-Martinez, Mariola A , Wagner, Charlotte , Davis, James A , Castaneda Puglianini, Omar , Dima, Danai , Bhutani, Manisha , Parrondo, Ricardo D , Freeman, Ciara L , Anderson, Larry D , Hosoya, Hitomi , Chhabra, Saurabh , Grajales-Cruz, Ariel F , Sborov, Douglas W , Patel, Krina , Hansen, Doris K , Costa, Luciano J , Merz, Maximilian , Sidana, Surbhi , Raza, Shahzad , Dhakal, Binod , Fandrei, David , Pan, Darren , Richard, Shambavi , Rees, Matthew J. , Costello, Patrick , Vazquez‐Martinez, Mariola , Pasvolsky, Oren , Puglianini, Omar Castañeda , Reshef, Ran , Dima, Danai , Nadeem, Omar , Chhabra, Saurabh , Grajales‐Cruz, Ariel , Gagelmann, Nico , Hansen, Doris K. , Costa, Luciano J. , Merz, Maximilian

Mayo Clinic

Blood | August 1, 2025 | Volume: 146 | Issue: 17 | Pages: 2063-2072

10.1182/blood.2025029773 | PMID 40749169 Get It

Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein–coupled receptor, family C, group 5, member D (GPRC5D)–targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
A Hybrid CNN-GRU Model for Real-Time Prediction of Sepsis Clinical Trajectories in the ICU
Hou, Grace Yao , Hanson, Andrew C. , Schulte, Phillip J. , Lal, Amos , Dong, Yue , Gajic, Ognjen, Zhong, Xiang , Lal, Amos , Dong, Yue , Hou, Grace Yao

Mayo Clinic

IEEE Robotics and Automation Letters | August 1, 2025 | Volume: 10 | Issue: 9 | Pages: 9565-9572

10.1109/lra.2025.3595040 Get It

Octreotide infusion as a treatment for hepatic hydrothorax in a hospital-at-home program: case report from Mayo Clinic
Webster, Leah W., Wachter, Corey, Turunen, Arto , Nordstrom, Charles W. , Dumic, Igor , Dumic, Igor , Paulson, Margaret R. , Maniaci, Michael J. , Wachter, Corey J., Turunen, Andrew

Mayo Clinic

Therapeutic Advances in Gastroenterology | July 31, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251362573 | PMID 40756179 Get It

Hepatic hydrothorax (HH) is a rare but serious complication of end-stage liver disease that is often refractory to conventional medical and procedural management. This case report describes a 75-year-old woman with HH secondary to cirrhosis from metabolic-associated steatotic liver disease. Her clinical course was marked by recurrent hospitalizations, refractory right-sided pleural effusion, and multiple unsuccessful interventions including diuretics, serial thoracenteses, an indwelling pleural catheter, and chemical pleurodesis. Notably, the persistence of pleural fluid despite resolution of ascites ultimately led to the formation of a thoracic fistula, with pleural drainage volumes exceeding 4 L/day. Further invasive procedures, such as transjugular intrahepatic portosystemic shunt or liver transplantation, were declined by the patient. She was enrolled in Mayo Clinic’s hospital-at-home (HaH) program, where continuous intravenous octreotide was initiated at a dose of 25 mcg/h. This resulted in a significant reduction in pleural output—from over 4000 mL to less than 100 mL daily. After clinical stabilization, the patient transitioned to subcutaneous octreotide and remained clinically stable for over 6 months, with improved quality of life and no significant adverse effects. To our knowledge, this is the first reported case of continuous intravenous octreotide infusion for HH administered safely in a home-based acute care setting. This case underscores the potential therapeutic role of octreotide in managing refractory HH and highlights the feasibility of delivering complex cirrhosis-related care through a HaH model with multidisciplinary collaboration. Further research is warranted to assess the long-term efficacy, safety, and cost-effectiveness of octreotide in this context and to explore broader application in home hospital environments.
Structured Application of Genetic Testing in a Pediatric Kidney Clinic
Salcedo-Giraldo, Jordy , Wink, K , Dadzie, Nicholas , Freiman, Andrew , Pyle, Louise C. , Gordish‐Dressman, Heather , Moxey‐Mims, Marva , Dahl, Neera K. , Guay‐Woodford, Lisa M. , Gulati, Ashima , Wink, Krista R , Pyle, Louise C , Dahl, Neera K

Mayo Clinic

Journal of the American Society of Nephrology | July 29, 2025 | Volume: 37 | Issue: 1 | Pages: 120-130

10.1681/asn.0000000816 | PMID 40728892 Get It

Key Points The growing knowledge of single-gene causes of pediatric-onset kidney diseases necessitates a structured application of genetic testing in practice. The clinical application of a combined nephrogenetics approach for management of kidney diseases is not well described in pediatric settings. Real-world application of a kidney genetics workflow highlights clinical value and challenges to be addressed for its successful implementation. Background The expanding knowledge of identifiable genetic contributions to pediatric inherited kidney diseases, and the increasing availability of genetic testing resources necessitates a combined nephrogenetics clinical approach. Although such models are described for adults, the effect of a structured nephrogenetics workflow on children with inherited kidney disease has not been rigorously evaluated. Methods Clinical and genetic data of patients aged younger than 1–21 years over a 10-year period between 2014 and 2024 from a single-center pediatric inherited kidney disease outpatient program were evaluated. Genetic variants were classified as pathogenic/likely pathogenic and variants of uncertain significance (VUS). Patients were grouped into “informative” or “uninformative” groups based on the effect of genetic test results on disease management and outcomes. Results Of the N =356 patients evaluated for a known or suspected inherited kidney disease, N =188 received clinical genetic testing. Of these, N =147 had an “informative” genetic test affecting at least one positive clinical outcome. Patients with an “informative” genetic test mostly harbored a pathogenic/likely pathogenic variant ( N =122). An additional N =25 had a VUS reclassified as a “VUS-of-interest” affecting a positive outcome measure. Genetic test results led to change in clinical diagnosis (reverse phenotyping, 46%), informed specific diagnosis-based treatment (46%), avoided unnecessary immunosuppression (27%) or kidney biopsy (18%), and guided extrarenal evaluation (72%) in patients with an informative test. Patients with a glomerular (odds ratio [OR]=5.23; 95% confidence interval [CI], 1.96 to 13.96) or a tubular functional disease (OR=2.17; 95% CI, 1.31 to 5.59) were more likely and those with a structural kidney disease (OR=0.39; 95% CI, 0.25 to 0.60) were less likely to receive a genetic test when compared with all other disease categories combined. Conclusions This workflow integrated multidisciplinary care for children with inherited kidney disease and describes a model for actionable clinical care plans after genetic testing. Informative genetic tests were associated with positive outcomes, and notable challenges include access to combined nephrology and genetics expertise for informed testing and an effective result return including VUS interpretation.
Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis
Covert, Lauren T. , Ardalan, Kaveh , Vasquez‐Canizares, Natalia , Jones, Madison E. , Correll, C. , Begezda, Alexis , Shenoi, Susan , Kovalick, Leonard K., Lapin, William Blaine, Tarvin, Stacey E. , Oliver, Melissa , Rodriguez, Martha , Marmor, Itay , Baszis, Kevin , Taxter, Alysha J. , Hanson, Andrew C. , Crowson, Cynthia S. , Yi, Belina Y. , Wahezi, Dawn M. , Hui‐Yuen, Joyce S , Mosa, Doaa Mosad , Wu, Eveline Y. , Orandi, Amir B.

Mayo Clinic

Clinical and Experimental Rheumatology | July 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/35pbbq | PMID 40737048 Get It

Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Awadallah, Andrew S. , Khalil, Yousuf H. , Bowen, Andrew J. , Ali, Hawa M. , Ring, Sydney , McCalla, Monet, Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Ekbom, Dale , Bowen, Andrew Jay , Awadallah, Andrew , Francis, David O , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | July 29, 2025 | Volume: 135 | Issue: 12 | Pages: 4767-4773

10.1002/lary.32464 | PMID 40726462 Get It

ABSTRACT Background Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence 4.
Percutaneous epidural spinal cord stimulation immediately reduces clonus in an individual with multiple sclerosis
Anders, Jennifer , Jahanian, Omid , Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Mills, Candee J. , Thoreson, Andrew R. , Larson, C. W., Sagen, Jessica, Grahn, Peter J. , Zhao, Kristin D. , Asp, Anders J , Fernandez, K A , Larson, Carol M, Sagen, Jessica A., Tobin, W Oliver , Trentadue, Taylor P , Jahanian, Omid , Larson, Carol M, Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal | July 28, 2025 | Volume: 32 | Issue: 1 | Pages: 144-147

10.1177/13524585251357143 | PMID 40719678 Get It

Clonus is a disabling symptom of upper motor neuron dysfunction in patients with multiple sclerosis (MS). We report immediate termination of mechanically evoked clonus by epidural lumbosacral spinal cord stimulation (ES) in a 58-year-old man with secondary progressive MS. This observation was captured during training using video and skin surface electromyography of soleus muscle activity. ES immediately reduced mechanically evoked clonus duration and cycle count compared to trials without stimulation, as determined by a Kruskal–Wallis test ( p < 0.05, n = 2–3 trials), and reverted to baseline status when stimulation was off.
Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy
Kuchenbecker, Lindsey A. , Hurst, Cheyenne , Huang, Yen-Ning , Carrasquillo, Minerva M. , Reddy, Joseph S. , Nguyen, Thuy , Casellas, Heidi L., Sotelo, Katie D., Reddy, Delila J., Opdenbosch, Bianca M., Tsai, Wei, Lucas, John A. , Willis, Floyd B. , Day, Gregory S. , Graff‐Radford, Neill R., Ertekin‐Taner, Nilüfer , Nho, Kwangsik, Hurst, Cheyenne D, Carrasquillo, Minerva M. , Day, Gregory S , Thompson, Kevin J. , Saykin, Andrew J. , Ramanan, Vijay K. , Graff‐Radford, Neill R. , Kalari, Krishna R.

Mayo Clinic

Alzheimer's & Dementia | July 28, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70505 | PMID 40717652 Get It

Abstract INTRODUCTION African American (AA) individuals are underrepresented in biomarker studies for Alzheimer's disease (AD). Biomarkers that reflect the heterogeneity of AD and achieve the greatest accuracy across populations are sorely needed. METHODS Untargeted proteome measurements were obtained using the SomaScan 7k platform to identify novel plasma biomarkers for AD in AA participants with clinical diagnoses of AD dementia ( n = 181) and cognitively unimpaired (CU, n = 142). Machine learning was used to identify a set of plasma proteins that yielded the best classification accuracy. RESULTS A set of 36 proteins achieved an area under the curve (AUC) of 0.94 to classify AD dementia versus CU, a 16% improvement over age, sex, and apolipoprotein E ( APOE) . This finding was replicated in multiple plasma and brain datasets (AUCs 0.73–0.97). Our findings underscore the importance of matrisome and cerebrovascular dysfunction in AD pathophysiology. DISCUSSION This study demonstrates the potential of biomarker discovery through untargeted plasma proteomics and machine learning. Highlights Conducted large‐scale plasma proteomics in Alzheimer's disease (AD) versus cognitively unimpaired controls. Machine learning biomarker discovery was replicated in an independent cohort. Novel set of proteins distinguishes AD versus controls with high accuracy (area under the curve [AUC] = 0.94). Achieved reproducibility across multiple replication cohorts (AUC = 0.73–0.97). Network analyses implicates matrisome biology and cerebrovascular dysfunction.